Generic Vevye Availability
Last updated on Nov 6, 2024.
Vevye is a brand name of cyclosporine ophthalmic, approved by the FDA in the following formulation(s):
VEVYE (cyclosporine - solution;ophthalmic)
-
Manufacturer: HARROW EYE
Approval date: May 30, 2023
Strength(s): 0.1% [RLD]
Has a generic version of Vevye been approved?
No. There is currently no therapeutically equivalent version of Vevye available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vevye. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ophthalmic compositions comprising ciclosporin
Patent 10,813,976
Issued: October 27, 2020
Inventor(s): Löscher Frank & Grillenberger Ralf & Engblom Johan
Assignee(s): NOVALIQ GMBHThe present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.
Patent expiration dates:
- September 22, 2037✓
- September 22, 2037
-
Semifluorinated compounds
Patent 11,154,513
Issued: October 26, 2021
Inventor(s): Scherer Dieter & Grillenberger Ralf & Löscher Frank & Voss Hartmut
Assignee(s): NOVALIQ GMBHThe present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.
Patent expiration dates:
- November 20, 2038✓✓
- November 20, 2038
-
Patent 11,413,323
Patent expiration dates:
- October 11, 2039✓
- October 11, 2039
-
Patent 12,059,449
Patent expiration dates:
- April 1, 2042✓✓
- April 1, 2042
-
Pharmaceutical composition for treatment of dry eye syndrome
Patent 8,614,178
Issued: December 24, 2013
Inventor(s): Theisinger Bastian & Theisinger Sonja & Günther Bernhard
Assignee(s): Novaliq GmbHThe invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
Patent expiration dates:
- December 13, 2030✓
- December 13, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 30, 2026 - NEW PRODUCT
More about Vevye (cyclosporine ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
